{"id":"W2137101132","doi":"10.1136/annrheumdis-2013-204655","title":"Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","year":2014,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":658,"is_retracted":false,"has_abstract":true,"ca_institutions":"Memorial University of Newfoundland","funders":"Astellas Pharma; Incyte; Eli Lilly and Company; CSL Behring; Tufts Medical Center; Celgene; Alexion Pharmaceuticals; Amgen; Pfizer; Regeneron Pharmaceuticals; Novo Nordisk; Teva Pharmaceutical Industries; GlaxoSmithKline","keywords":"Medicine; Ustekinumab; Psoriatic arthritis; Internal medicine; Placebo; Psoriasis; Psoriasis Area and Severity Index; Rheumatology; Clinical endpoint; Gastroenterology; Arthritis; Surgery; Tumor necrosis factor alpha; Randomized controlled trial; Immunology; Adalimumab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003122997,0.001411609,0.002439147,0.0003666549,0.0004893573,0.0008421395,0.000682725,0.00196319,0.003520635],"category_scores_gemma":[0.002141306,0.0007283766,0.001607409,0.0003797544,0.001040256,0.0009818737,0.0003652523,0.002717269,0.0007671911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006899225,"about_ca_system_score_gemma":0.0009791184,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006310702,"about_ca_topic_score_gemma":0.001470164,"domain_scores_codex":[0.9990051,0.0006348236,0.00007576221,0.0001095977,0.00008133588,0.00009341564],"domain_scores_gemma":[0.9987625,0.0003560587,0.0003902574,0.00007051539,0.00008178977,0.0003388417],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9674522,0.005853169,0.001725093,0.0005396688,0.0005933049,0.00004675705,0.00008392809,0.000208516,0.004376501,0.00003757529,0.0005350822,0.01854829],"study_design_scores_gemma":[0.8661686,0.1248469,0.006921059,0.00003972103,0.0004764167,0.00008395504,0.00002191596,0.0002775617,0.0006259492,0.00006675636,0.0004596272,0.00001156753],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917379,0.005393965,0.00024237,0.0003413396,0.0001536022,0.0009151167,0.0004146561,0.0000454077,0.0007557143],"genre_scores_gemma":[0.9937384,0.002295235,0.0006070847,0.0005655385,0.0003364648,0.0009955766,0.000589554,0.0000105605,0.0008616494],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003520635,"threshold_uncertainty_score":0.01651621,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03503453515663549,"score_gpt":0.303285057102635,"score_spread":0.2682505219459995,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}